{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:25:53Z","timestamp":1787315153607,"version":"build-2736575974"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802641"],"award-info":[{"award-number":["81802641"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Whether the HLX-02 plus pertuzumab offers superior efficacy compared to the HLX-02 plus pyrotinib in the early-stage setting remains unclear, highlighting a critical gap in evidence for optimizing neoadjuvant therapy selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of neoadjuvant chemotherapy regimens combining the trastuzumab biosimilar HLX-02 with either pertuzumab or pyrotinib in patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This is a retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study enrolled patients with HER2-positive breast cancer who received neoadjuvant therapy at The First Affiliated Hospital of University of Science and Technology of China between October 2021 and July 2024. Participants were divided into two treatment groups: those receiving docetaxel, carboplatin, HLX\u201102 plus pertuzumab (TCbHP group), and those receiving docetaxel, carboplatin, HLX\u201102 (a\n                      <jats:italic toggle=\"yes\">trastuzumab biosimilar<\/jats:italic>\n                      ) plus pyrotinib (TCbHPy group). To minimize selection bias, propensity score matching (PSM) was applied in a 1:2 ratio before evaluating efficacy and safety. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included safety outcomes, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 101 patients were initially included. After PSM, 55 patients were selected (TCbHP group:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 36; TCbHPy group:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19). The overall pCR rates were comparable between the groups (TCbHP group: 58.3% vs TCbHPy group: 52.6%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.778). Subgroup analysis showed that amonghormone receptor\u2013positive (HR+) patients, pCR rates were 50.0% in the TCbHP group and 44.4% in the TCbHPy group. For HR negative (HR\u2212) patients, pCR rates were 63.6% and 60.0%, respectively. The overall incidence of adverse events was 80.6% in the TCbHP group and 94.7% in the TCbHPy group. Notably, non-hematologic toxicities differed significantly between the groups, with a markedly higher incidence of diarrhea (grade \u2a7e3+: 47.3%) observed in the TCbHPy group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both HLX\u201102\u2011based neoadjuvant regimens exhibited comparable efficacy in achieving pCR in patients with HER2\u2011positive breast cancer. These findings indicate that HLX\u201102, whether combined with pertuzumab or pyrotinib, represents a viable neoadjuvant strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261470682","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T01:49:51Z","timestamp":1787104191000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer"],"prefix":"10.1177","volume":"18","author":[{"given":"Weifang","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China"},{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China"},{"name":"Department of Breast Surgery, Anhui Provincial Cancer Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6569-7123","authenticated-orcid":false,"given":"Qilin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China"},{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China"},{"name":"Department of Breast Surgery, Anhui Provincial Cancer Hospital, Hefei, China"},{"name":"Graduated School, Wannan Medical University, Wuhu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-828X","authenticated-orcid":false,"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230026, China"},{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China"},{"name":"Department of Breast Surgery, Anhui Provincial Cancer Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230026, China"},{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China"},{"name":"Department of Breast Surgery, Anhui Provincial Cancer Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.02.002"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"issue":"5","key":"e_1_3_4_5_2","first-page":"1550","article-title":"Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2\/neu gene product","volume":"50","author":"Fendly BM","year":"1990","unstructured":"Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2\/neu gene product. Cancer Res 1990; 50(5): 1550\u20131558.","journal-title":"Cancer Res"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4285"},{"key":"e_1_3_4_7_2","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski MX","year":"1999","unstructured":"Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26(4 Suppl 12): 60\u201370.","journal-title":"Semin Oncol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043186"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-307"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30863-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00676-9"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3692"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5610"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0237"},{"issue":"8","key":"e_1_3_4_18_2","article-title":"Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial","volume":"26","author":"Awada A","year":"2021","unstructured":"Awada A, Colomer R, Inoue K, et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist 2021; 26(8): e1327\u2013e1338.","journal-title":"Oncologist"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30702-6"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02708-3"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2478"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5791"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01694-5"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00716-6"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00475-w"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174270"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04196-9"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2183117"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-70875-6_24"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040709"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.5858\/133.4.611"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612795"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1744-3"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.007"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07657-2"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk134"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9885-0"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3407"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00849-9"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261470682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261470682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261470682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:49:41Z","timestamp":1787312981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261470682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["10.1177\/17588359261470682"],"URL":"https:\/\/doi.org\/10.1177\/17588359261470682","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261470682"}}